Bulletin
Investor Alert

Market Pulse Archives

April 15, 2021, 6:06 a.m. EDT

Blood clots as prevalent with Pfizer and Moderna vaccine as with AstraZeneca's: study

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Pfizer Inc. (PFE)
  • X
    Moderna Inc. (MRNA)
  • X
    AstraZeneca PLC ADR (AZN)

or Cancel Already have a watchlist? Log In

By Steve Goldstein

A study by Oxford University found the number of people who receive blood clots after getting vaccinated with a coronavirus vaccine are about the same for those who get Pfizer /zigman2/quotes/202877789/composite PFE +0.05% and Moderna /zigman2/quotes/205619834/composite MRNA -6.19% vaccines as they are for the AstraZeneca /zigman2/quotes/200304487/composite AZN +1.36% vaccine that was produced with the university's help. According to the study, 4 in 1 million people experience cerebral venous thrombosis after getting the Pfizer or Moderna vaccine, versus 5 in 1 million people for the AstraZeneca vaccine. The risk of getting CVT is much higher for those who get COVID-19 -- 39 in a million patients -- than it is for those who get vaccinated. AstraZeneca's vaccine use has been halted or limited in many countries on blood clot concerns.

/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 39.97
+0.02 +0.05%
Volume: 54.22M
May 5, 2021 4:02p
P/E Ratio
23.37
Dividend Yield
3.90%
Market Cap
$222.85 billion
Rev. per Employee
$533,860
loading...
/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 162.84
-10.75 -6.19%
Volume: 18.87M
May 5, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$69.47 billion
Rev. per Employee
$617,996
loading...
/zigman2/quotes/200304487/composite
US : U.S.: Nasdaq
$ 53.65
+0.72 +1.36%
Volume: 7.36M
May 5, 2021 4:00p
P/E Ratio
35.25
Dividend Yield
2.55%
Market Cap
$139.05 billion
Rev. per Employee
$365,423
loading...

This Story has 0 Comments
Be the first to comment
More News In
Markets

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.